Synergy Pharma Cmn (SGYP) 5.61 $SGYP Synergy

New Post Public Reply Private Reply Replies (0) Message Board

Sep 25, 2016 at 11:04 PM

Synergy Pharma Cmn (SGYP) 5.61 $SGYP

Synergy Pharmaceuticals to Present at OctoberINVESTfest 2016
BusinessWire - Fri Sep 23, 8:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company will present at the OctoberINVESTfest Conference on Wednesday, September 28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences in New York.
SGYP: 5.61 (+0.03)

Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
PR Newswire - Thu Sep 15, 6:40AM CDT
The global Drug Manufacturers space has seen moderate growth over the last five years due to increased demand for medicines, especially from emerging economies. This morning, Stock-Callers.com has issued research reports on four equities, namely, Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and Apricus Biosciences Inc. (NASDAQ: APRI). Download the free research reports on these stocks today:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), PTX: 0.65 (+0.03), APRI: 0.35 (-0.05)

Synergy Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference
BusinessWire - Wed Sep 07, 8:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Rodman & Renshaw Conference on Monday, September 12, 2016 at 5:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New York.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update
BusinessWire - Mon Aug 08, 4:00PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30, 2016.
SGYP: 5.61 (+0.03)

Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), DRRX: 1.70 (-0.04), BIOD: 0.45 (+0.03)

Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Mon Aug 01, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 5.61 (+0.03)

Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 5.61 (+0.03)

Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), IRWD: 15.72 (-0.15)

These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 5.61 (+0.03)

Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 5.61 (+0.03), DB: 12.75 (-0.25)

Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 5.61 (+0.03), IRWD: 15.72 (-0.15)

What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What: After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), IRWD: 15.72 (-0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flying Car Regulatory Sandbox Begins in UAE

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Qatar Foundation Spurs Sport-Driven Empowerment Moves

Here we go, diving into the serious talk of the moment: sports pushing boundaries to uplift society's underdogs. Envision yourself in the halls of Wilton Park, where the thinkers, the dreamers, and the doers convened in the name of change. Qatar Foundation ain't just sitting pretty; they're championing the cause to harness sport for impactful social threads across the...

Tragedy Highlights Need for E-bike Safety Overhaul

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

BarrelPick.com Launches for Bourbon Aficionados

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

USPS Rolls Out Christmas Cookie Stamps Nationwide

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Papa John's Faces Class Action Over Misleading Info

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Insta360 Expands with Times Square Flagship Store

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

Why Liver Nurture Taps into Health Sector Trends

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Med Spa Visits: Key Insights from Lindsey Smith

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...